CN102186820B - Rassf1a表达和人癌细胞增殖的荧光调节剂 - Google Patents

Rassf1a表达和人癌细胞增殖的荧光调节剂 Download PDF

Info

Publication number
CN102186820B
CN102186820B CN2009801406819A CN200980140681A CN102186820B CN 102186820 B CN102186820 B CN 102186820B CN 2009801406819 A CN2009801406819 A CN 2009801406819A CN 200980140681 A CN200980140681 A CN 200980140681A CN 102186820 B CN102186820 B CN 102186820B
Authority
CN
China
Prior art keywords
rassf1a
cancer
cells
cell
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2009801406819A
Other languages
English (en)
Chinese (zh)
Other versions
CN102186820A (zh
Inventor
密尔顿·L·布朗
凯瑟琳·D·谢赫
米凯尔·佩奇
帕索·班纳吉
尚卡尔·加格德施
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Georgetown University
Original Assignee
Georgetown University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Georgetown University filed Critical Georgetown University
Publication of CN102186820A publication Critical patent/CN102186820A/zh
Application granted granted Critical
Publication of CN102186820B publication Critical patent/CN102186820B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Electroluminescent Light Sources (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CN2009801406819A 2008-08-15 2009-08-14 Rassf1a表达和人癌细胞增殖的荧光调节剂 Expired - Fee Related CN102186820B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18905908P 2008-08-15 2008-08-15
US61/189,059 2008-08-15
PCT/US2009/004681 WO2010019271A1 (en) 2008-08-15 2009-08-14 Fluorescent regulators of rassf1a expression and human cancer cell proliferation

Publications (2)

Publication Number Publication Date
CN102186820A CN102186820A (zh) 2011-09-14
CN102186820B true CN102186820B (zh) 2013-08-28

Family

ID=41279343

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801406819A Expired - Fee Related CN102186820B (zh) 2008-08-15 2009-08-14 Rassf1a表达和人癌细胞增殖的荧光调节剂

Country Status (9)

Country Link
US (1) US10457639B2 (enExample)
EP (2) EP2323982B1 (enExample)
JP (2) JP2012500197A (enExample)
CN (1) CN102186820B (enExample)
AT (1) ATE547403T1 (enExample)
AU (1) AU2009282451B2 (enExample)
BR (1) BRPI0917411A2 (enExample)
CA (1) CA2734225A1 (enExample)
WO (1) WO2010019271A1 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8097712B2 (en) 2007-11-07 2012-01-17 Beelogics Inc. Compositions for conferring tolerance to viral disease in social insects, and the use thereof
US8962584B2 (en) 2009-10-14 2015-02-24 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Compositions for controlling Varroa mites in bees
PL2545182T4 (pl) 2010-03-08 2017-11-30 Monsanto Technology Llc Cząsteczki polinukeotydu do regulacji genów w roślinach
US8637679B2 (en) 2011-03-11 2014-01-28 Council Of Scientific And Industrial Research Process for the isolation of organic compounds useful for the treatment of cancer
EP2755988B1 (en) 2011-09-13 2018-08-22 Monsanto Technology LLC Methods and compositions for weed control
UA115535C2 (uk) 2011-09-13 2017-11-27 Монсанто Текнолоджи Ллс Спосіб та композиція для боротьби з бур'янами (варіанти)
US10760086B2 (en) 2011-09-13 2020-09-01 Monsanto Technology Llc Methods and compositions for weed control
US10806146B2 (en) 2011-09-13 2020-10-20 Monsanto Technology Llc Methods and compositions for weed control
MX377067B (es) 2011-09-13 2025-03-07 Monsanto Technology Llc Métodos y composiciones para el control de malezas.
US10829828B2 (en) 2011-09-13 2020-11-10 Monsanto Technology Llc Methods and compositions for weed control
CA2848680C (en) 2011-09-13 2020-05-19 Monsanto Technology Llc Methods and compositions for weed control
WO2013040117A1 (en) 2011-09-13 2013-03-21 Monsanto Technology Llc Methods and compositions for weed control
AR091143A1 (es) 2012-05-24 2015-01-14 Seeds Ltd Ab Composiciones y metodos para silenciar la expresion genetica
CN105358695B (zh) 2013-01-01 2019-07-12 A.B.种子有限公司 将dsRNA引入植物种子以调节基因表达的方法
US10683505B2 (en) 2013-01-01 2020-06-16 Monsanto Technology Llc Methods of introducing dsRNA to plant seeds for modulating gene expression
UA121846C2 (uk) 2013-03-13 2020-08-10 Монсанто Текнолоджи Ллс Спосіб та гербіцидна композиція для контролю видів рослини роду lolium
EP2971185A4 (en) 2013-03-13 2017-03-08 Monsanto Technology LLC Methods and compositions for weed control
WO2014151317A1 (en) * 2013-03-15 2014-09-25 Rush University Medical Center Methods for treating cancer
US10568328B2 (en) 2013-03-15 2020-02-25 Monsanto Technology Llc Methods and compositions for weed control
US9850496B2 (en) 2013-07-19 2017-12-26 Monsanto Technology Llc Compositions and methods for controlling Leptinotarsa
MX359191B (es) 2013-07-19 2018-09-18 Monsanto Technology Llc Composiciones y métodos para controlar leptinotarsa.
UY35817A (es) 2013-11-04 2015-05-29 Us Agriculture ?composiciones y métodos para controlar infestaciones de plagas y parásitos de los artrópodos?.
UA119253C2 (uk) 2013-12-10 2019-05-27 Біолоджикс, Інк. Спосіб боротьби із вірусом у кліща varroa та у бджіл
EP3116303B1 (en) 2014-01-15 2020-07-22 Monsanto Technology LLC Methods and compositions for weed control using epsps polynucleotides
EP3420809A1 (en) 2014-04-01 2019-01-02 Monsanto Technology LLC Compositions and methods for controlling insect pests
AU2015280252A1 (en) 2014-06-23 2017-01-12 Monsanto Technology Llc Compositions and methods for regulating gene expression via RNA interference
WO2015200539A1 (en) 2014-06-25 2015-12-30 Monsanto Technology Llc Methods and compositions for delivering nucleic acids to plant cells and regulating gene expression
WO2016018887A1 (en) 2014-07-29 2016-02-04 Monsanto Technology Llc Compositions and methods for controlling insect pests
PL3256589T3 (pl) 2015-01-22 2022-02-21 Monsanto Technology Llc Kompozycje i sposoby kontrolowania leptinotarsa
EP3302053B1 (en) 2015-06-02 2021-03-17 Monsanto Technology LLC Compositions and methods for delivery of a polynucleotide into a plant
EP3302030A4 (en) 2015-06-03 2019-04-24 Monsanto Technology LLC METHOD AND COMPOSITIONS FOR INTRODUCING NUCLEIC ACIDS IN PLANTS
WO2017023916A1 (en) 2015-08-05 2017-02-09 Georgetown University Small molecule androgen receptor inhibitors and methods of use thereof
JP7236382B2 (ja) * 2017-06-12 2023-03-09 昇平 宮田 抗癌剤及びその使用
CN107266356B (zh) * 2017-07-25 2020-06-26 山西省生物研究院有限公司 一种作为自分泌运动因子抑制剂的咔唑类化合物及其制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008051523A2 (en) * 2006-10-23 2008-05-02 Georgetown University Carbazole derivatives useful as medicaments in cancer therapy

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2235815A1 (de) * 1972-07-21 1974-01-31 Bayer Ag Polyazofarbstoffe
NL8720442A (nl) 1986-08-18 1989-04-03 Clinical Technologies Ass Afgeefsystemen voor farmacologische agentia.
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
AU643141B2 (en) 1991-03-15 1993-11-04 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
GB9215361D0 (en) 1992-07-20 1992-09-02 Wellcome Found Heterocyclic compounds
WO1995003279A1 (en) * 1993-07-26 1995-02-02 Eisai Co., Ltd. Sulfonamide and sulfonic ester derivatives each having tricyclic hetero ring
JP3690825B2 (ja) * 1993-07-26 2005-08-31 エーザイ株式会社 三環式ヘテロ環含有スルホンアミドおよびスルホン酸エステル誘導体
CA2186412A1 (en) * 1995-10-31 1997-05-01 Katherine S. Takaki Ethylamino carbazole melatonergic agents
IL136737A0 (en) * 1997-12-22 2001-06-14 Bayer Ag Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
AU3840000A (en) * 1999-04-20 2000-11-02 Meiji Seika Kaisha Ltd. Tricyclic compounds
KR20020069215A (ko) 1999-12-16 2002-08-29 아사히 가세이 가부시키가이샤 신규한 치환기를 갖는 3환성 화합물
WO2001083452A1 (en) 2000-04-28 2001-11-08 Asahi Kasei Kabushiki Kaisha Novel tricyclic compounds
US6506901B2 (en) * 2000-07-17 2003-01-14 Wyeth Substituted 2-(S)-hydroxy-3-(piperidin-4-yl-methylamino)-propyl ethers and substituted 2-aryl-2-(R)-hydroxy-1-(piperidin-4-yl-methyl)-ethylamine β-3 adrenergic receptor agonists
CN101849953B (zh) 2000-12-18 2012-04-25 株式会社医药分子设计研究所 炎症性细胞因子产生游离抑制剂
WO2002060867A2 (en) * 2001-01-29 2002-08-08 Insight Strategy And Marketing Ltd Carbazole derivatives and their uses as heparanase inhibitors
JPWO2002074306A1 (ja) 2001-03-19 2004-07-08 旭化成ファーマ株式会社 脂肪肝治療薬
GB0319151D0 (en) * 2003-08-14 2003-09-17 Glaxo Group Ltd Novel compounds
WO2006002908A1 (en) 2004-06-29 2006-01-12 Jadolabs Gmbh Carbazole-derived pharmaceutical compositions
CA2575046A1 (en) 2004-08-18 2006-02-23 Ciba Specialty Chemicals Holding Inc. Oxime ester photoinitiators
ITMI20051523A1 (it) 2005-08-03 2007-02-04 Acraf Composto del 3-ammino-carbazolo composizione farmaceutica che lo contiene e metodo per prepararlo
WO2007026201A1 (en) 2005-09-01 2007-03-08 Council Of Scientific And Industrial Research A pharmaceutical composition useful for the treatment of prostate cancer
CN1807413B (zh) 2005-09-28 2010-05-05 中国医学科学院医药生物技术研究所 咔唑磺酰胺衍生物及其制备方法
BRPI0617364A2 (pt) 2005-10-13 2011-07-26 Orchid Res Lab Ltd compostos heterocÍclicos como inibidores de pstat3/il-6
IL186935A0 (en) 2006-10-31 2008-02-09 Veridex Llc Prostate cancer field effect analysis methods and kits
US20090220980A1 (en) 2007-12-28 2009-09-03 John Wayne Cancer Institute Use of methylation status of mint loci and tumor-related genes as a marker for melanoma and breast cancer
KR101673621B1 (ko) 2008-03-24 2016-11-07 노파르티스 아게 아릴술폰아미드-계 매트릭스 메탈로프로테아제 억제제

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008051523A2 (en) * 2006-10-23 2008-05-02 Georgetown University Carbazole derivatives useful as medicaments in cancer therapy

Also Published As

Publication number Publication date
JP2012500197A (ja) 2012-01-05
JP2014148545A (ja) 2014-08-21
BRPI0917411A2 (pt) 2015-12-01
EP2323982A1 (en) 2011-05-25
CA2734225A1 (en) 2010-02-18
AU2009282451A1 (en) 2010-02-18
AU2009282451B2 (en) 2014-02-13
WO2010019271A1 (en) 2010-02-18
CN102186820A (zh) 2011-09-14
HK1158206A1 (en) 2012-07-13
EP2323982B1 (en) 2012-02-29
WO2010019271A8 (en) 2011-03-31
US20110152339A1 (en) 2011-06-23
EP2484666A1 (en) 2012-08-08
US10457639B2 (en) 2019-10-29
ATE547403T1 (de) 2012-03-15

Similar Documents

Publication Publication Date Title
CN102186820B (zh) Rassf1a表达和人癌细胞增殖的荧光调节剂
JP4989976B2 (ja) 翻訳開始阻害剤としての３−３−二置換オキシインドール
CN101360422B (zh) 致癌Ras特异性细胞毒化合物及其使用方法
US9132102B2 (en) Stilbene analogs and methods of treating cancer
CA2953079C (en) Intermittent dosing of mdm2 inhibitor
JP2020513789A (ja) ヘテロ二官能性化合物を用いた調整可能な内因性タンパク質分解
JP2014012706A (ja) 抗がん活性を有する化合物
US20100130579A1 (en) Cancer therapy
US11312676B2 (en) Small molecule stimulators of steroid receptor coactivator proteins and their use in the treatment of cancer
FR2921927A1 (fr) Imidazo[1,2-a]quinoxalines et derives pour le traitement des cancers
JP2014531402A5 (enExample)
JP2014531402A (ja) 新規アニリン誘導体及びこれの用途（Ｎｏｖｅｌａｎｉｌｉｎｅｄｅｒｉｖａｔｉｖｅｓａｎｄｕｓｅｔｈｅｒｅｏｆ）
AU2015314772A1 (en) Compositions and methods for treatment of prostate carcinoma
CN1918148B (zh) 取代的苯并咪唑和它们诱导细胞凋亡的用途
AU2015225828B2 (en) Mcl-1 modulating compounds for cancer treatment
US10450295B2 (en) Method of using an indolinone molecule and derivatives for inhibiting liver fibrosis and hepatitis
AU2014202507B2 (en) Fluorescent regulators of RASSF1A expression and human cancer cell proliferation
US9175001B2 (en) [1,3] dioxolo [4,5-g] [1,2,4] triazolo [1,5-a] quinoline derivatives as inhibitors of the late SV40 factor (LSF) for use in treating cancer
HK1158206B (en) Fluorescent regulators of rassf1a expression and human cancer cell proliferation
CN103130774A (zh) 具有酪氨酸激酶抑制作用的化合物及其制备方法和应用
WO2019022556A1 (ko) 신규한 벤질리덴아세톤 유도체 및 이의 용도
JP2025523463A (ja) Ｍｙｃ調節を含む組み合わせ療法
WO2018076537A1 (zh) D-3-磷酸甘油酸脱氢酶别构抑制剂及其应用
TWI415611B (zh) 喹啉衍生物及其應用
WO2013121385A1 (fr) Utilisation de dérivés de carbazolophénone pour le traitement du cancer

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20130828

Termination date: 20180814